Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

Pierga, Jean-Yves; Petit, Thierry; Delozier, Thierry; Ferrero, Jean-Marc; Campone, Mario; Gligorov, Joseph; Lerebours, Florence; Roché, Henri; Bachelot, Thomas; Charafe-Jauffret, Emmanuelle; Pavlyuk, Maria; Kraemer, Sandrine; Bidard, François-Clément; Viens, Patrice

Pierga, Jean-Yves; Petit, Thierry; Delozier, Thierry; Ferrero, Jean-Marc; Campone, Mario; Gligorov, Joseph; Lerebours, Florence; Roché, Henri; Bachelot, Thomas; Charafe-Jauffret, Emmanuelle; Pavlyuk, Maria; Kraemer, Sandrine; Bidard, François-Clément; Viens, Patrice.

Affiliation

Pierga JY; Institut Curie, Paris, France.

Lancet Oncol ; 13(4): 375-84, 2012 Apr.

Article in En | MEDLINE | ID: mdl-22377126

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Inflammatory Breast Neoplasms/drug therapy; Adult; Aged; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Asthenia/chemically induced; Bevacizumab; Combined Modality Therapy; Female; Humans; Inflammatory Breast Neoplasms/pathology; Inflammatory Breast Neoplasms/surgery; Middle Aged; Nausea/chemically induced; Neoadjuvant Therapy/methods; Neoplasm Staging; Neutropenia/chemically induced; Postoperative Care; Receptor, ErbB-2/analysis; Trastuzumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Inflammatory Breast Neoplasms / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google